SCHEDULE: Citadel Entities and Kenneth Griffin Disclose Significant Stake in Allogene Therapeutics
Beneficial Ownership Report
Citadel Advisors LLC, Citadel Securities LLC, and Kenneth Griffin have disclosed beneficial ownership of Allogene Therapeutics, Inc. common stock, with Griffin holding a 6.1% stake.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively reported beneficial ownership of 10,203,329 shares of Allogene Therapeutics, Inc. common stock, representing 4.7% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively reported beneficial ownership of 3,142,822 shares, representing 1.4% of the class.
- Kenneth Griffin, through his controlling interests in the Citadel entities, reported beneficial ownership of an aggregate of 13,346,151 shares, constituting 6.1% of Allogene Therapeutics' outstanding common stock.
- The reported percentages are based on 218,730,809 shares of Allogene Therapeutics, Inc. common stock outstanding as of May 9, 2025, as reported in the issuer's Form 10-Q filed on May 13, 2025.
- The beneficial ownership is primarily shared voting and shared dispositive power, with no sole voting or sole dispositive power reported by any of the filing entities or Kenneth Griffin.
- The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Allogene Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing no positive or negative operational or financial news about the issuer. The sentiment is neutral.
Industry Context
This filing indicates a significant passive investment by a major financial institution and its principal in Allogene Therapeutics, Inc., a biotechnology company. Such disclosures are common for large investment firms managing diversified portfolios and do not inherently suggest a strategic shift or direct involvement in the issuer's operations, especially given the stated purpose of not influencing control.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional stake may be viewed positively by some investors, potentially signaling confidence from a major fund, though the filing explicitly states the purpose is not to influence control.
Key Dates
| Date | Description |
|---|---|
| 2023-10-13 | Date of power of attorney filing for Seth Levy on behalf of Kenneth Griffin, previously filed with the SEC as an attachment to a Schedule 13G for Allakos Inc. |
| 2025-05-09 | Date as of which 218,730,809 shares of Allogene Therapeutics, Inc. common stock were outstanding, according to the issuer's Form 10-Q. |
| 2025-05-13 | Date Allogene Therapeutics, Inc.'s Form 10-Q was filed with the Securities and Exchange Commission. |
| 2025-07-09 | Date of the event which required the filing of this Schedule 13G statement. |
| 2025-07-16 | Date of filing of this Schedule 13G statement and the date for the holdings of the reporting persons as of the opening of the market. |
Keywords
Allogene Therapeutics, Citadel Advisors, Citadel Securities, Kenneth Griffin, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.